Synonyms: CR845 | D-Phe-D-Phe-D-Leu-D-Lys-[γ-(4-N-piperidinyl)amino carboxylic acid] | FE-202845 | Kapruvia® | Korsuva® | SEQ ID NO: 2 [6]
difelikefalin is an approved drug (FDA (2021), EMA (2022))
Compound class:
Peptide
Comment: Difelikefalin is a first-in-class, peripherally acting, highly selective peptide agonist of the κ-opioid receptor, that was developed for potential to treat chronic itch [4] and it is claimed in patent US7402564B1 [6]. This patent provides extensive results from preclinical testing, assessing the analgesic and anti-pruritic potential of difelikefalin.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Cowan A, Kehner GB, Inan S. (2015)
Targeting Itch with Ligands Selective for κ Opioid Receptors. Handb Exp Pharmacol, 226: 291-314. [PMID:25861786] |
2. Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F, KALM-1 Trial Investigators. (2020)
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. N Engl J Med, 382 (3): 222-232. [PMID:31702883] |
3. Hercz D, Jiang SH, Webster AC. (2020)
Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev, 12: CD011393. [PMID:33283264] |
4. Janecka A, Perlikowska R, Gach K, Wyrebska A, Fichna J. (2010)
Development of opioid peptide analogs for pain relief. Curr Pharm Des, 16 (9): 1126-35. [PMID:20030621] |
5. Manenti L, Fenaroli P. (2022)
Difelikefalin for pruritus associated with renal disease. Drugs Today (Barc), 58 (9): 427-435. [PMID:36102903] |
6. Schteingart CD, Menzaghi F, Jiang G, Alexander RV, Sueiras-Diaz J, Spencer RH, Chalmers DT, Luo Z. (2008)
Synthetic peptide amides. Patent number: US7402564 B1. Assignee: Cara Therapeutics, Inc.. Priority date: 10/11/2006. Publication date: 22/07/2008. |